Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21867306 | 0.91 | POLB (0.41) | RIPK1HTR1ACYP2D6CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL21800426 | 0.89 | POLB (0.40) | RIPK1HTR1ACYP2D6CYP1A2CYP3A4 | |
| SCHEMBL20564560 | 0.83 | RIPK1 (0.52) | RIPK1HTR1ACYP2D6HSD17B10CYP1A2 | |
| SCHEMBL20565278 | 0.82 | RIPK1 (0.49) | RIPK1HTR1ACYP2D6HSD17B10CYP1A2 | |
| Hydrochloric Acid SCHEMBL20565293 | 0.81 | RIPK1 (0.48) | RIPK1HTR1ACYP2D6HSD17B10CYP1A2 | |
| SCHEMBL1292282 | 0.77 | PANK3 (0.40) | RIPK1HSD17B10CYP3A4ALDH1A1POLB | |
| SCHEMBL20565610 | 0.77 | MEN1 (0.40) | RIPK1HTR1ACYP2D6CYP1A2CYP3A4 | |
| SCHEMBL21867414 | 0.76 | RIPK1 (0.47) | RIPK1HTR1ACYP2D6CYP1A2POLB | |
| SCHEMBL21800392 | 0.75 | RIPK1 (0.48) | RIPK1HTR1ACYP2D6CYP1A2CYP3A4 | |
| SCHEMBL21868482 | 0.74 | MEN1 (0.54) | CYP2D6HSD17B10CYP1A2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885HTR1A 4610/4885CYP2D6 3745/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885HTR1A 4610/4885CYP2D6 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.